Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
The present disclosure relates to methods of treating cancer by administering a compound, which is an Fibroblast Growth Factor Receptor (FGFR) inhibitor, in combination with enfortumab vedotin.
1. A method of treating cancer in a patient, comprising administering to said patient:
(i) pemigatinib, or a pharmaceutically acceptable salt thereof; and
(ii) enfortumab vedotin;
wherein the cancer is bladder cancer.
2. The method of claim 1 , wherein pemigatinib and enfortumab vedotin are administered simultaneously.
3. The method of claim 1 , wherein pemigatinib and enfortumab vedotin are administered sequentially.
4. The method of claim 1 , wherein pemigatinib is administered orally.
5. The method of claim 1 , wherein pemigatinib is administered in a daily dose of about 1 mg to about 20 mg.
6. The method of claim 1 , wherein pemigatinib is administered in a daily dose of about 13.5 mg.
7. The method of claim 1 , wherein pemigatinib is administered in a daily dose of about 9 mg.
8. The method of claim 1 , wherein enfortumab vedotin is administered intravenously.
9. The method of claim 1 , wherein enfortumab vedotin is administered as an intravenous infusion in a dosage of about 0.5 mg/kg to about 2.0 mg/kg.
10. The method of claim 1 , wherein enfortumab vedotin is administered as an intravenous infusion in a dosage of about 1.25 mg/kg.
11. The method of claim 1 , further comprising administering one or more additional therapeutic agents.
12. The method of claim 11 , comprising administering one additional therapeutic agent.
13. The method of claim 12 , wherein the additional therapeutic agent in an inhibitor of PD-1 or PD-L1.